CTSB and infection: Due to its low toxicity, it has been employed therapeutically to inhibit host and pathogen cysteine proteases in a variety of infection models encompassing bacterial (55, –, 57), fungal (58), and parasitic (59) infections, and for multiple viruses (60, 61), including SARS-CoV-2 (62, 63).